Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients

Autores
Rollet, Raquel; Vaustat, Daniela; Laube, Gerardo
Año de publicación
2025
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Fil: Clostridioides difficile is an etiological agent of diarrhea, and the use of antibiotics is one of the main risk factors for infection. Antimicrobials used for treatment are vancomycin (VAN), metronidazole (MET), and fidaxomicin. Resistant strains have been detected, exhibiting regional and institutional differences. The aim of this work was to determine the susceptibility profile of C. difficile clinical isolates to 14 antimicrobials, and to compare resistance among participating centers. A total of 208 consecutive isolates recovered from seven Argentinian hospitals between January 2018 and March 2020 were studied. MIC was determined by the agar dilution method (CLSI-M100 29ED). Azithromycin (AZM), clindamycin (CLI), ertapenem (ETP), imipenem (IMI), levofloxacin (LEV), linezolid (LNZ), meropenem (MER), metronidazole (MET),moxifloxacin (MOX), piperacillin---tazobactam (PTZ), rifaximin (RFX), teicoplanin (TEI), tigecy-cline (TGC), and VAN, were tested. The results were analyzed with SPSS 21.0. Chi-square wasused to compare data, and statistical significance was set at p < 0.05. Susceptibility percentageswere as follows: VAN, TEI, and MET, 100%; TGC, 97.6%; PTZ, 96.2%; LNZ, 95.2%; MER, 99.5%; ETP,60.9%; IMI, 42.8%; RFX, 55.6%; LEV, 48.6%; MOX, 46.1%; CLI, 29.9%; and azithromycin, 17.8%.Significant differences in resistance among centers were observed for: RFX (16.7%---91.7%), CLI(41.2%---86.1%), MOX (22.9%---97.2%), IMI (0%---55.6%), and azithromycin (62.5%---97.2%). Multidrugresistance (MDR) was detected in 80 isolates (38.5%), of which 63 (78.7%) were resistant to threefamilies of antimicrobial agents and 17 (21.3%) were resistant to four. The most frequent combi-nations were RFX---MOX---CLI, present in 48 (60.0%) isolates, and RFX---IMI---MOX---CLI in 17 (21.3%)isolates. VAN, TEI, and MET were the most active antimicrobials in vitro against C. difficilestrains. MER was the most active carbapenem, whereas IMI was the least active. We highlightthe differences across institutions that could reflect epidemiological characteristics, and/orthe dissemination of clones in each institution.
Fil: Rollet, Raquel. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.
Fil: Vaustat, Daniela. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.
Fil: Laube, Gerardo. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.
Materia
ARTICULO
MICROBIOLOGIA
CLOSTRIDIOIDES DIFFICILE
ANTIBIOTICOS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
Repositorio
Repositorio Institucional (Fundacion Barceló)
Institución
Fundación H. A. Barceló
OAI Identificador
oai:repositorio.barcelo.edu.ar:123456789/1120

id RIBARCELO_50703762c63fd69a0699b330a855e593
oai_identifier_str oai:repositorio.barcelo.edu.ar:123456789/1120
network_acronym_str RIBARCELO
repository_id_str a
network_name_str Repositorio Institucional (Fundacion Barceló)
spelling Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patientsRollet, RaquelVaustat, DanielaLaube, GerardoARTICULOMICROBIOLOGIACLOSTRIDIOIDES DIFFICILEANTIBIOTICOSFil: Clostridioides difficile is an etiological agent of diarrhea, and the use of antibiotics is one of the main risk factors for infection. Antimicrobials used for treatment are vancomycin (VAN), metronidazole (MET), and fidaxomicin. Resistant strains have been detected, exhibiting regional and institutional differences. The aim of this work was to determine the susceptibility profile of C. difficile clinical isolates to 14 antimicrobials, and to compare resistance among participating centers. A total of 208 consecutive isolates recovered from seven Argentinian hospitals between January 2018 and March 2020 were studied. MIC was determined by the agar dilution method (CLSI-M100 29ED). Azithromycin (AZM), clindamycin (CLI), ertapenem (ETP), imipenem (IMI), levofloxacin (LEV), linezolid (LNZ), meropenem (MER), metronidazole (MET),moxifloxacin (MOX), piperacillin---tazobactam (PTZ), rifaximin (RFX), teicoplanin (TEI), tigecy-cline (TGC), and VAN, were tested. The results were analyzed with SPSS 21.0. Chi-square wasused to compare data, and statistical significance was set at p < 0.05. Susceptibility percentageswere as follows: VAN, TEI, and MET, 100%; TGC, 97.6%; PTZ, 96.2%; LNZ, 95.2%; MER, 99.5%; ETP,60.9%; IMI, 42.8%; RFX, 55.6%; LEV, 48.6%; MOX, 46.1%; CLI, 29.9%; and azithromycin, 17.8%.Significant differences in resistance among centers were observed for: RFX (16.7%---91.7%), CLI(41.2%---86.1%), MOX (22.9%---97.2%), IMI (0%---55.6%), and azithromycin (62.5%---97.2%). Multidrugresistance (MDR) was detected in 80 isolates (38.5%), of which 63 (78.7%) were resistant to threefamilies of antimicrobial agents and 17 (21.3%) were resistant to four. The most frequent combi-nations were RFX---MOX---CLI, present in 48 (60.0%) isolates, and RFX---IMI---MOX---CLI in 17 (21.3%)isolates. VAN, TEI, and MET were the most active antimicrobials in vitro against C. difficilestrains. MER was the most active carbapenem, whereas IMI was the least active. We highlightthe differences across institutions that could reflect epidemiological characteristics, and/orthe dissemination of clones in each institution.Fil: Rollet, Raquel. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.Fil: Vaustat, Daniela. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.Fil: Laube, Gerardo. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.Instituto Universitario de Ciencias de la Salud – Fundación BarcelóLitterio, MirtaCastello, LilianaFernández-Canigia, LilianaBarberis, ClaudiaLegaria, María CristinaAzula, NataliaMaldonado, María LauraPredari, Silvia CarlaRossettih, María Adelaida2025-09-172025-11-19T19:52:27Zinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.barcelo.edu.ar/handle/123456789/1120enginfo:eu-repo/semantics/openAccessreponame:Repositorio Institucional (Fundacion Barceló)instname:Fundación H. A. Barceló2026-04-24T11:45:20Zoai:repositorio.barcelo.edu.ar:123456789/1120instacron:BARCELOInstitucionalhttp://repositorio.barcelo.edu.ar/greenstone/cgi-bin/library.cgiUniversidad privadaNo correspondehttp://repositorio.barcelo.edu.ar/greenstone/cgi-bin/oaiserver.cgilrodriguezares@barcelo.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2026-04-24 11:45:20.932Repositorio Institucional (Fundacion Barceló) - Fundación H. A. Barcelófalse
dc.title.none.fl_str_mv Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients
title Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients
spellingShingle Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients
Rollet, Raquel
ARTICULO
MICROBIOLOGIA
CLOSTRIDIOIDES DIFFICILE
ANTIBIOTICOS
title_short Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients
title_full Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients
title_fullStr Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients
title_full_unstemmed Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients
title_sort Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients
dc.creator.none.fl_str_mv Rollet, Raquel
Vaustat, Daniela
Laube, Gerardo
author Rollet, Raquel
author_facet Rollet, Raquel
Vaustat, Daniela
Laube, Gerardo
author_role author
author2 Vaustat, Daniela
Laube, Gerardo
author2_role author
author
dc.contributor.none.fl_str_mv Litterio, Mirta
Castello, Liliana
Fernández-Canigia, Liliana
Barberis, Claudia
Legaria, María Cristina
Azula, Natalia
Maldonado, María Laura
Predari, Silvia Carla
Rossettih, María Adelaida
dc.subject.none.fl_str_mv ARTICULO
MICROBIOLOGIA
CLOSTRIDIOIDES DIFFICILE
ANTIBIOTICOS
topic ARTICULO
MICROBIOLOGIA
CLOSTRIDIOIDES DIFFICILE
ANTIBIOTICOS
dc.description.none.fl_txt_mv Fil: Clostridioides difficile is an etiological agent of diarrhea, and the use of antibiotics is one of the main risk factors for infection. Antimicrobials used for treatment are vancomycin (VAN), metronidazole (MET), and fidaxomicin. Resistant strains have been detected, exhibiting regional and institutional differences. The aim of this work was to determine the susceptibility profile of C. difficile clinical isolates to 14 antimicrobials, and to compare resistance among participating centers. A total of 208 consecutive isolates recovered from seven Argentinian hospitals between January 2018 and March 2020 were studied. MIC was determined by the agar dilution method (CLSI-M100 29ED). Azithromycin (AZM), clindamycin (CLI), ertapenem (ETP), imipenem (IMI), levofloxacin (LEV), linezolid (LNZ), meropenem (MER), metronidazole (MET),moxifloxacin (MOX), piperacillin---tazobactam (PTZ), rifaximin (RFX), teicoplanin (TEI), tigecy-cline (TGC), and VAN, were tested. The results were analyzed with SPSS 21.0. Chi-square wasused to compare data, and statistical significance was set at p < 0.05. Susceptibility percentageswere as follows: VAN, TEI, and MET, 100%; TGC, 97.6%; PTZ, 96.2%; LNZ, 95.2%; MER, 99.5%; ETP,60.9%; IMI, 42.8%; RFX, 55.6%; LEV, 48.6%; MOX, 46.1%; CLI, 29.9%; and azithromycin, 17.8%.Significant differences in resistance among centers were observed for: RFX (16.7%---91.7%), CLI(41.2%---86.1%), MOX (22.9%---97.2%), IMI (0%---55.6%), and azithromycin (62.5%---97.2%). Multidrugresistance (MDR) was detected in 80 isolates (38.5%), of which 63 (78.7%) were resistant to threefamilies of antimicrobial agents and 17 (21.3%) were resistant to four. The most frequent combi-nations were RFX---MOX---CLI, present in 48 (60.0%) isolates, and RFX---IMI---MOX---CLI in 17 (21.3%)isolates. VAN, TEI, and MET were the most active antimicrobials in vitro against C. difficilestrains. MER was the most active carbapenem, whereas IMI was the least active. We highlightthe differences across institutions that could reflect epidemiological characteristics, and/orthe dissemination of clones in each institution.
Fil: Rollet, Raquel. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.
Fil: Vaustat, Daniela. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.
Fil: Laube, Gerardo. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.
description Fil: Clostridioides difficile is an etiological agent of diarrhea, and the use of antibiotics is one of the main risk factors for infection. Antimicrobials used for treatment are vancomycin (VAN), metronidazole (MET), and fidaxomicin. Resistant strains have been detected, exhibiting regional and institutional differences. The aim of this work was to determine the susceptibility profile of C. difficile clinical isolates to 14 antimicrobials, and to compare resistance among participating centers. A total of 208 consecutive isolates recovered from seven Argentinian hospitals between January 2018 and March 2020 were studied. MIC was determined by the agar dilution method (CLSI-M100 29ED). Azithromycin (AZM), clindamycin (CLI), ertapenem (ETP), imipenem (IMI), levofloxacin (LEV), linezolid (LNZ), meropenem (MER), metronidazole (MET),moxifloxacin (MOX), piperacillin---tazobactam (PTZ), rifaximin (RFX), teicoplanin (TEI), tigecy-cline (TGC), and VAN, were tested. The results were analyzed with SPSS 21.0. Chi-square wasused to compare data, and statistical significance was set at p < 0.05. Susceptibility percentageswere as follows: VAN, TEI, and MET, 100%; TGC, 97.6%; PTZ, 96.2%; LNZ, 95.2%; MER, 99.5%; ETP,60.9%; IMI, 42.8%; RFX, 55.6%; LEV, 48.6%; MOX, 46.1%; CLI, 29.9%; and azithromycin, 17.8%.Significant differences in resistance among centers were observed for: RFX (16.7%---91.7%), CLI(41.2%---86.1%), MOX (22.9%---97.2%), IMI (0%---55.6%), and azithromycin (62.5%---97.2%). Multidrugresistance (MDR) was detected in 80 isolates (38.5%), of which 63 (78.7%) were resistant to threefamilies of antimicrobial agents and 17 (21.3%) were resistant to four. The most frequent combi-nations were RFX---MOX---CLI, present in 48 (60.0%) isolates, and RFX---IMI---MOX---CLI in 17 (21.3%)isolates. VAN, TEI, and MET were the most active antimicrobials in vitro against C. difficilestrains. MER was the most active carbapenem, whereas IMI was the least active. We highlightthe differences across institutions that could reflect epidemiological characteristics, and/orthe dissemination of clones in each institution.
publishDate 2025
dc.date.none.fl_str_mv 2025-09-17
2025-11-19T19:52:27Z
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://repositorio.barcelo.edu.ar/handle/123456789/1120
url https://repositorio.barcelo.edu.ar/handle/123456789/1120
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Instituto Universitario de Ciencias de la Salud – Fundación Barceló
publisher.none.fl_str_mv Instituto Universitario de Ciencias de la Salud – Fundación Barceló
dc.source.none.fl_str_mv reponame:Repositorio Institucional (Fundacion Barceló)
instname:Fundación H. A. Barceló
reponame_str Repositorio Institucional (Fundacion Barceló)
collection Repositorio Institucional (Fundacion Barceló)
instname_str Fundación H. A. Barceló
repository.name.fl_str_mv Repositorio Institucional (Fundacion Barceló) - Fundación H. A. Barceló
repository.mail.fl_str_mv lrodriguezares@barcelo.edu.ar
_version_ 1863375299753803776
score 13.05261